About: Saratoga Opthalmology

A multicenter study adds evidence that intravitreal ziv-aflibercept, a low-cost formulation of aflibercept originally developed as a systemic chemotherapy agent, is safe for treatment of retinal diseases. Source: AAO

• Posted on: Nov 6 2017
• By: Saratoga Opthalmology

This cross-sectional study describes the phenotypical characteristics of AMD patients carrying a rare variant in the complement factor H gene. Source: AAO

• Posted on: Nov 6 2017
• By: Saratoga Opthalmology

This randomized sham-controlled trial evaluated the safety and efficacy of corneal crosslinking for patients who developed corneal ectasia after laser refractive surgery. Source: AAO

• Posted on: Nov 6 2017
• By: Saratoga Opthalmology

The FDA has approved latanoprostene bunod (Vyzulta), a nitric oxide-donating prostaglandin analog, for reducing IOP in patients with open-angle glaucoma or ocular hypertension. Source: AAO

• Posted on: Nov 3 2017
• By: Saratoga Opthalmology